Antiphospholipid antibodies and the coagulation cascade

Rheumatic Disease Clinics of North America

Volumn 27, Issue 3, 2001, Pages 573-586

  Anglés Cano, Eduardo ^a   Guillin, Marie Claude ^b  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR; FIBRIN; FIBRINOGEN; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTHROMBIN; THROMBIN;

ANTIBODY DETECTION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; MEMBRANE STRUCTURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; REVIEW; RISK ASSESSMENT; THROMBOCYTE; THROMBOSIS;

EID: 0034865785     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70221-0     Document Type: Article

References (43)

1. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
2. Clustering of lipid bound annexin V may explain its anticoagulant effect
3. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
4. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of phospholipid-bound prothrombin
5. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells
6. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis
7. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism
8. The coagulation cascade: Initiation, maintenance, and regulation
9. Static and dynamic lipid asymmetry in cell membranes
10. Regulation of blood coagulation
11. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex
12. Factor XI activation in a revised model of blood coagulation
13. Prothrombin as cofactor for antiphospholipids
14. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
15. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles
16. Enhancement of thrombin-thrombomodulin-catalyzed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids: Possible physiological significance of phosphatidylethanolamine in anticoagulant activity of thrombomodulin
17. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein
18. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and β2-glycoprotein I (and other proteins)
19. Epitopes on β2-GPI recognized by anticardiolipin antibodies
20. High affinity binding of β2-glycoprotein I to human endothelial cells is mediated by annexin II
21. Transcellular metabolism of neutrophil-derived leukotriene A4 by human platelets. A potential cellular source of leukotriene C4
22. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies
23. Surface-dependent reactions of the vitamin K-dependent enzyme complexes
24. Impaired catalytic function of activated protein C: A new manifestation of lupus anticoagulant
25. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H)
26. A hydrophobic sequence at position 313-316 (LeuAla-Phe-Trp) in the fifth domain of apolipoprotein H (β2-glycoprotein I) is crucial for cardiolipin binding
27. Antiphospholipid antibodies directed against a combination of phospholipid with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?
28. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro
29. The plot thickens: How thrombin modulates blood clotting
30. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets
31. The plasma carboxypeptidases and the regulation of the plasminogen system
32. Antiphospholipid antibody syndrome: New insights on thrombogenic mechanisms
33. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin V binding to phospholipids: A "lupus procoagulant" phenomenon
34. Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder
35. Inhibition of the tissue factor-factor VII mediated activation of coagulation factor X by a monoclonal IgM antibody expressing lupus anticoagulant activity
36. The effect of membrane composition on the hemostatic balance
37. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies
38. Tissue factor in atherosclerosis
39. Dynamics of molecular motion at single-crystal surfaces
40. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes
41. Solution structure of the smallest cofactor-active fragment of thrombomodulin
42. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells
43. Lipid-protein interactions in blood coagulation